Use of the Intermittent Abdominal Pressure Ventilation to guarantee speech in a tracheostomized Amyotrophic Lateral Sclerosis patient

n/

Patient organ and effective dose estimation in CT: comparison of four software applications

Background: Radiation dose in computed tomography (CT) has become a topic of high interest due to the increasing numbers of CT examinations performed worldwide. Hence, dose tracking and organ dose calculation software are increasingly used. We evaluated the organ dose variability associated with the use of different software applications or calculation methods. Methods: We tested four commercial software applications on CT protocols actually in use in our hospital: CT-Expo, NCICT, NCICTX, and Virtual Dose. We compared dose coefficients, estimated organ doses and effective doses obtained by the four software applications by varying exposure parameters. Our results were also compared with estimates reported by the software authors. Results: All four software applications showed dependence on tube voltage and volume CT dose index, while only CT-Expo was also dependent on other exposure parameters, in particular scanner model and pitch caused a variability till 50%. We found a disagreement between our results and those reported by the software authors (up to 600%), mainly due to a different extent of examined body regions. The relative range of the comparison of the four software applications was within 35% for most organs inside the scan region, but increased over the 100% for organs partially irradiated and outside the scan region. For effective doses, this variability was less evident (ranging from 9 to 36%). Conclusions: The two main sources of organ dose variability were the software application used and the scan region set. Dose estimate must be related to the process used for its calculation

Performance of three model-based iterative reconstruction algorithms using a CT task-based image quality metric

In this study we evaluated the task-based image quality of a low contrast clinical task for the abdomen protocol (e.g., pancreatic tumour) of three different CT vendors, exploiting three model-based iterative reconstruction (MBIR) levels. We used three CT systems equipped with a full, partial, advanced MBIR algorithms. Acquisitions were performed on a phantom at three dose levels. Acquisitions were reconstructed with a standard kernel, using filtered back projection algorithm (FBP) and three levels of the MBIR. The noise power spectrum (NPS), the normalized one (nNPS) and the task-based transfer function (TTF) were computed following the method proposed by the American Association of Physicists in Medicine task group report-233 (AAPM TG-233). Detectability index (d') of a small lesion (small feature; 100 HU and 5-mm diameter) was calculated using non-prewhitening with eye-filter model observer (NPWE).The nNPS, NPS and TTF changed differently depending on CT system. Higher values of d' were obtained with advanced-MBIR, followed by full-MBIR and partial-MBIR.Task-based image quality was assessed for three CT scanners of different vendors, considering a clinical question. Detectability can be a tool for protocol optimisation and dose reduction since the same dose levels on different scanners correspond to different d' values.Comment: 7 pages, 5 figures, 3 table

Utilização de xiloglucana na embriogênese somática a partir de embriões zigóticos de dendezeiro (Elaeis guineensis Jacq.).

O objetivo deste trabalho foi testar diferentes meios de cultura contendo misturas de XG e de Gelrite

Synthetic thiosemicarbazones as a new class of Mycobacterium tuberculosis protein tyrosine phosphatase A inhibitors.

Abstract Mycobacterium tuberculosis secretes two protein tyrosine phosphatases as virulence factors, PtpA and PtpB. Inhibition studies of these enzymes have shown significant attenuation of the M. tuberculosis growth in vivo. As PtpA mediates many effects on the regulation of host signaling ensuring the intracellular survival of the bacterium we report, for the first time, thiosemicarbazones as potential novel class of PtpA inhibitors. Several compounds were synthesized and biologically evaluated, revealing interesting results. Enzyme kinetic assays showed that compounds 5, 9 and 18 are non-competitive inhibitors of PtpA, with Ki values ranging from 1.2 to 5.6 µM. Modeling studies clarified the structure-activity relationships observed in vitro and indicated a possible allosteric binding site in PtpA structure. To the best of our knowledge, this is the first disclosure of potent non-competitive inhibitors of PtpA with great potential for future studies and development of analogues